UC1010: Phase I/II started

Umecrine's Umecrine Mood AB subsidiary began a double-blind, placebo-controlled, Swedish Phase I/II trial to evaluate up to 40 mg/mL subcutaneous UC1010 in about 120 women. The trial will evaluate sin...